Skajaa N, Adelborg K, Horvath-Puho E, Rothman KJ, Henderson VW, Thygesen LC, Sorensen HT. Stroke and risk of mental disorders compared with matched general population and Myocardial infarction comparators. Stroke. 2022 Jul;53(7):2287-98. doi: 10.1161/STROKEAHA.121.037740
John NM, Wright SJ, Gavan SP, Vass CM. The role of information provision in economic evaluations of non-invasive prenatal testing: a systematic review. Eur J Health Econ. 2019 Nov;20(8):1123-31. doi: 10.1007/s10198-019-01082-x
Pead E, Megaw R, Cameron J, Fleming A, Dhillon B, Trucco E, Macgillivray T. Automated detection of age-related macular degeneration in color fundus photography: a systematic review. Surv Ophthalmol. 2019 Jul 1;64(4):498-511. doi: 10.1016/j.survophthal.2019.02.003
Wilson MR, Bergman A, Chevrou-Severac H, Selby R, Smyth M, Kerrigan MC. Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom. Eur J Health Econ. 2017 Mar;19(2):229-40. doi: 10.1007/s10198-017-0879-5.
Jeyakumar G, Tu JV, Austin PC, Hall R, Jin A, Manuel D, Silver FL, Swartz R, Chu A, Khan AM, Kapral MK. Rural-urban differences in stroke incidence, mortality and risk factor prevalence in Ontario. Poster presented at the American Heart Association/American Stroke Association 2017 International Stroke Conference; February 21, 2017. Houston, TX. [abstract] Stroke. 2017 Feb; 48(Suppl_1):180. doi: 10.1161/str.48.suppl_1.wp180
Shah S, Murthy S, Karanth S, Bershad EM, Venkatasubba Rao CP, Suarez JI. Treatment of ischemic stroke with recombinant tissue plasminogen-activator in pregnancy: a population study. Poster presented at the International Stroke Conference 2014; February 2014. San Diego, CA. [abstract] Stroke. 2014 Feb; 45(Suppl 1). doi: doi.org/10.1161/str.45.suppl_1.wp61Stroke. 2014;45:AWP61
Murthy S, Shah S, Karanth S, Shastri A, Bershad E, Suarez JI. Clinical outcomes following thrombolysis for acute ischemic stroke in patients with primary brain tumors: a nationwide population study. Poster presented at the International Stroke Conference 2014; February 2014. San Diego, CA. [abstract] Stroke. 2014 Feb; 45(Suppl 1). doi: 10.1161/str.45.suppl_1.tmp14Stroke. 2014;45:ATMP14
Murthy S, Shah S, Karanth S, Shastri A, Bershad E, Suarez JI. Clinical outcomes following thrombolysis for acute ischemic stroke in patients with systemic malignancy: a nationwide case-control study. Poster presented at the International Stroke Conference 2014; February 2014. San Diego, CA. [abstract] Stroke. 2014 Feb; 45(Suppl 1).
Murthy SB, Karanth S, Shah S, Shastri A, Rao CP, Bershad EM, Suarez JI. Thrombolysis for acute ischemic stroke in patients with cancer: a population study. Stroke. 2013 Dec;44(12):3573-6. doi: 10.1161/STROKEAHA.113.003058
Beard SM, von Scheele BG, Nuki G, Pearson IV. Cost-effectiveness of febuxostat in chronic gout. Eur J Health Econ. 2013 May;Advance online publication.
Henk HJ, Kaye JA, Rothman KJ, Becker LK, Legg JC, Li X. Variation by age in neutropenic complications among patients with cancer receiving chemotherapy. Community Oncol. 2013 Jan 1;10(1):16-26.
Oglesby A, Sherif B, Odom D, Leahy M, Qian Y. Time and costs associated with preparing and administering zoledronic acid in patients with breast or prostate cancer and metastatic bone disease. Community Oncol. 2009 Nov 1;6(11):494-502.
Earnshaw SR, Jackson D, Farkouh R, Schwamm L. Cost-effectiveness of patient selection using penumbral-based MRI for intravenous thrombolysis. Stroke. 2009 May 1;40(5):1710-20.
Earnshaw SR, Jackson DL, Farkouh RA, Schwamm LH. Cost-effectiveness of MRI-based selection of patients for intravenous thrombolysis. Poster presented at the 2009 International Stroke Conference; February 2009. San Diego, CA. [abstract] Stroke. 2009 Apr; 40(4):E192-3.
Buchanan A, Sugg Skinner C, Calingaert B, Schildkraut J, King R, Marcom K. Cancer genetic counseling in rural North Carolina oncology clinics: program establishment and patient characteristics. Community Oncol. 2009;6(2):70-7.
Greiner W, Lehmann K, Earnshaw S, Bug C, Sabatowski R. Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany. Eur J Health Econ. 2006 Dec 1;7(4):290-6.
Earnshaw SR, Joshi AV, Wilson MR, Rosand J. Cost-effectiveness of recombinant activated factor VII in the treatment of intracerebral hemorrhage. Stroke. 2006 Nov 28;37(11):2751-8.
Earnshaw SR, Joshi AV, Wilson MR, Rosand J. Cost-effectiveness of recombinant activated factor vii in the treatment of intracerebral hemorrhage. Poster presented at the 2006 International Stroke Conference; February 17, 2006. [abstract] Stroke. 2006 Nov; 37(11):2751.
Djousse L, Rothman KJ, Cupples LA, Arnett DK, Ellison RC. Relation between serum albumin and carotid atherosclerosis the NHLBI family heart study. Stroke. 2003 Jan 1;34(1):53-7.
Clarkson TB, Anthony MS, Mikkola TS, St. Clair RW. Comparison of tibolone and conjugated equine estrogens effects on carotid artery atherosclerosis of postmenopausal monkeys. Stroke. 2002 Nov;33(11):2700-3.
Lehmann K, Radbruch L, Gockel HH, Neighbors D, Nuyts G. Costs of opioid therapy for chronic nonmalignant pain in Germany: an economic model comparing transdermal fentanyl (Duragesic) with controlled release morphine. Eur J Health Econ. 2002;3:111-9. doi: 10.1007/s10198-002-0097-6.